
WSW, NY, November 16th, 2026, FinanceWire Buyers are committing capital to prolonged drug delivery and hospital medicines. PolyPid approaches its November 28 FDA goal date with positive Phase 3 results,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CRMD | Cormedix | 5.27 | -4.41 | -45.56% |
| Name | Price | % Change | |
|---|---|---|---|
| $5.27 | -45.56% |

WSW, NY, November 16th, 2026, FinanceWire Buyers are committing capital to prolonged drug delivery and hospital medicines. PolyPid approaches its November 28 FDA goal date with positive Phase 3 results,

Cormedix Inc. (($CRMD)) has held its Q3 earnings call. Read on for the main highlights of the call. CorMedix’s earnings call struck a strategically optimistic tone as management highlighted the

Oppenheimer analyst Les Sulewski lowered the firm’s price target on CorMedix (CRMD) to $13 from $15 and keeps an Outperform rating on the shares. Following Q3 results and its follow-up

Cormedix Inc. (CRMD) has disclosed a new risk, in the Share Price & Shareholder Rights category. Following the acquisition, he notes that Heron stockholders will hold a sizable 18.3% stake

Reports Q3 revenue $54.52M, consensus $52.77M. Joseph Todisco, Chairman & Chief Executive Officer of CorMedix (CRMD), commented, “CorMedix will be entering 2027 with two meaningful potential growth drivers. First, our

Cormedix ( ($CRMD) ) has provided an announcement. On November 9, 2026, CorMedix and Heron announced a definitive asset purchase agreement under which CorMedix would acquire substantially all of Heron’s

RBC Capital analyst Leonid Timashev raised the firm’s price target on CorMedix (CRMD) to $15 from $14 and keeps an Outperform rating on the shares. The company announced the acquisition

Needham analyst Serge Belanger raised the firm’s price target on CorMedix (CRMD) to $14 from $12 and keeps a Buy rating on the shares. The firm is adjusting its model

An update from Cormedix ( ($CRMD) ) is now available. On November 8, 2026, CorMedix and Heron Therapeutics entered an agreement under which CorMedix would acquire substantially all of Heron’s

CorMedix (CRMD) and Heron Therapeutics (HRTX) announced that they have entered into a definitive asset purchase agreement under which CorMedix will acquire substantially all of the assets of Heron, and
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 30, 2027TBA | $404.05M | $-0.15 | $51.58M | -0.01 | 6.59 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.